Honigman Miller Schwartz and Cohn LLP
07/08/2025 | Press release | Distributed by Public on 07/08/2025 11:17
Announcements | Jul 8, 2025Honigman Advises CB Biotechnology on Up to $254 Million Pending Acquisition of Theratechnologies
Honigman advised CB Biotechnology - an affiliate of Future Pak, a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products - on signing its take private acquisition of Theratechnologies (Nasdaq: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies. The deal is worth up to $254 million.
The transaction is expected to close on or about November 30, 2025, subject to customary closing conditions.
Honigman advised CB Biotechnology in the acquisition. The team was led by Corporate Partners Nicholas Pedersen and Jeffrey H. Kuras, with support from Associate Gareth T. Ulmer. Financing counsel was provided by Partners Kimberly A. Dudek and David J. Axelson, with support from Associate Sarah A. Schade-McCarter.
Read more about the acquisition here.
Honigman Miller Schwartz and Cohn LLP published this content on July 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 08, 2025 at 17:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io